National Institute of Allergy and Infectious Diseases (NIAID). NIAID ChemDB, HIV Drugs in Development. Accessed April 4, 2023 Frontier Biotechnologies Inc. Efficacy and safety of albuvirtide for injection combined with LPV/r for treatment of HIV-1-infected patients failed first-line antiretroviral therapy. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on February 18, 2015. NLM Identifier: NCT02369965. Accessed April 4, 2023

The TALENT study (TALENT) findings, which were presented at the 11th International AIDS Society (IAS) Conference on HIV Science, showed that a two-drug regimen was as effective and safe as multi-drug therapies What side effects might albuvirtide cause? What side effects might albuvirtide cause? What side effects might albuvirtide cause? The 2021 Guidelines fully updated the epidemiological and etiological characteristics of HIV and AIDS, clinical manifestations and stages, antiretroviral therapies for HIV , post-exposure prophylaxis treatment and management of the whole continuum of the HIV infection.Wu H, Yao C, Lu R, et al. Albuvirtide, the first long-acting HIV fusion inhibitor, suppressed viral replication in HIV-infected adults. Abstract presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 9–12, 2012; San Francisco, CA. Abstract H-554. Accessed April 4, 2023 In the reproductive toxicity studies in rat and rabbit, the No Observed Adverse Effect Level(NOAEL) of Albuvirtideintravenously injected were 4 folds and 2 folds of humanequivalent dose, respectively, and no toxicity to parental fertility and embryonic development was observed. Since no clinical data are availablein pregnant women, it is not recommended that this product be used for pregnant women. One goal of HIV research is to identify new drugs that have fewer side effects. The following side effects were observed in some of the studies of albuvirtide listed above. ChiCTR-TRC-13003140

The two-drug regimen with different targets is the future trend of ART research. It is worthy and we are looking forward to continuing to develop new HIV combinations of high efficacy and good tolerability for our patients." Step 3: Withdraw 6 mL of sodium chloride solution from remaining88mLof 0.9%sodium chloride solutionin Step 1 and inject into each AIKENING TMvial tomix thoroughly. Chin Med J (Engl) article, 2020: Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study The agreement is subject to customary regulatory approval in Austria and is expected to complete early in 2022. Purpose: The purpose of this study is to establish the optimal dosage of a regimen consisting of albuvirtide plus the investigational broadly neutralizing antibody (bNAb) 3BNC117. The study will also evaluate the safety and effectiveness of this regimen as maintenance therapy. 8Study Purpose: The purpose of this 48-week open-label trial was to compare the efficacy of albuvirtide plus lopinavir/ritonavir to two NRTIs plus lopinavir/ritonavir. The phase 3 trial randomized 418 patients; more than 25% of patients were female and more than 70% patients had resistance to at least two drug classes. Further, approximately 25% of patients had CD4 cell count of less than 100, indicating advanced HIV disease with highly compromised immunity, who were at high risk of opportunistic diseases and death. In other words, this was a patient population that was relatively difficult to treat. Kennedy, K.; Graham, B.; Droste, R.; Fernandes, L.; Narbaitz, R. Microtox(TM) and Ceriodaphnia dubia toxicity of BKME with powdered activated carbon treatment(TM). Water SA 2000, 26, 205–216. [ Google Scholar]